Compare Merck & Co., Inc. (MRK) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Orion Office REIT Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Orion Office REIT Inc trades at $2.55 (market cap $151.74M). The key difference: Merck & Co., Inc. is far larger — about 2413.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.01%). Which is the better fit depends on your goals.
| MRK | ONL | |
|---|---|---|
Market Cap | $366.28B | $151.74M |
Sector | Health | Real Estate |
52-Week High | $156.43 | $3.00 |
52-Week Low | $77.60 | $1.93 |
Enterprise Value | $413.04B | $568.67M |
Dividend Yield | 2.29% | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Orion Office REIT (ONL) trades at $2.66, down 1.85% on the day, with a bearish technical outlook and mixed fundamentals. The company reported a Q2 2026 earnings beat but continues to post significant net losses, with a negative net income margin of -65.66% in 2025. Despite a low price-to-book ratio of 0.24, indicating potential undervaluation, declining revenues and negative profitability metrics highlight ongoing challenges in its office property portfolio.
The outlook remains cautious due to persistent operational losses and high debt levels, though analyst sentiment is split evenly between Buy and Hold. Key risks include further revenue erosion and interest expense pressures, while potential catalysts hinge on successful portfolio repositioning and stabilized office demand as highlighted in recent earnings calls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
